title: [Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma].
abstract: The Tissue Polypeptide Antigen (TPA) is an oncofetal antigen widely used in the diagnosis and follow-up of several urothelial cancers. Its urinary and serum detection is performed by means of RIA technique. We determined urinary and serum TPA in 30 patients with bladder cancer who underwent a transurethral resection. Ten out of 30 patients were correctly diagnosed by serum TPA, 22 by urinary TPA. The ANOVA test showed a statistically significant correlation between grade and urinary TPA between stage and serum TPA. Urinary TPA showed a good sensibility in low grade and moreover in Ta stage carcinoma. Serum TPA increased its performance with higher grade carcinoma and in presence of a muscle infiltration, but it never reached a sufficient sensibility to be considered a bladder cancer marker. In conclusion the simultaneous determination of urinary and serum TPA does not give more information than the urinary determination alone.
authors.affiliation: Istituto di Nefro-Urologia, Università di Torino.
authors.forename: A
authors.initials: A
authors.lastname: Tizzani
authors.forename: G
authors.initials: G
authors.lastname: Casetta
authors.forename: A
authors.initials: A
authors.lastname: Cavallini
authors.forename: P
authors.initials: P
authors.lastname: Piana
authors.forename: P
authors.initials: P
authors.lastname: Piantino
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000032:analysis* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D010455:Peptides / Q000032:analysis*; D011237:Predictive Value of Tests; D011863:Radioimmunoassay; D019396:Tissue Polypeptide Antigen; D001749:Urinary Bladder Neoplasms / Q000032:analysis* / Q000473:pathology
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D010455:Peptides; D019396:Tissue Polypeptide Antigen
vernacular_title: Determinazione sierica ed urinaria del Tissue Polypeptide Antigen (TPA) nei pazienti affetti da carcinoma vescicale.